

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Arovella Therapeutics Limited
<b>ABN</b>	35 090 987 250

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Debora Barton
<b>Date of last notice</b>	16 December 2022

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct		
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Director related entity		
<b>Date of change</b>	04 December 2023		
<b>No. of securities held prior to change</b>		<b>Shares</b>	<b>Options</b>
	Direct	263,157	2,400,000
	Indirect	-	-
	<b>Total</b>	<b>263,157</b>	<b>2,400,000</b>
<b>Class</b>	ALAAA unlisted options		
<b>Number acquired</b>	618,000 ALAAA unlisted options		
<b>Number disposed</b>	0		
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Options issued in lieu of cash fees per Notice of AGM dated 12 October 2023		

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

No. of securities held after change		Shares	Options
	Direct	263,157	3,018,000
	Indirect	-	-
	<b>Total</b>	<b>263,157</b>	<b>3,018,000</b>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Options approved by shareholders at AGM held 10 November 2023		

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Arovella Therapeutics Limited
<b>ABN</b>	35 090 987 250

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Gary Phillips
<b>Date of last notice</b>	12 July 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect		
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Director related entity		
<b>Date of change</b>	04 December 2023		
<b>No. of securities held prior to change</b>		<b>Shares</b>	<b>Options</b>
	Direct	-	-
	Indirect	722,222	1,600,000
	<b>Total</b>	<b>722,222</b>	<b>1,600,000</b>
<b>Class</b>	ALAAA Unlisted options		
<b>Number acquired</b>	618,000 ALAAA unlisted options		
<b>Number disposed</b>	-		
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Options issued in lieu of cash fees per Notice of AGM dated 12 October 2023		

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

No. of securities held after change		Shares	Options
	Direct	-	-
	Indirect	722,222	2,128,000
	<b>Total</b>	<b>722,222</b>	<b>2,128,000</b>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		Options approved by shareholders at AGM held 10 November 2023	

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Arovella Therapeutics Limited
<b>ABN</b>	35 090 987 250

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Elizabeth Stoner
<b>Date of last notice</b>	5 May 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct		
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Director related entity		
<b>Date of change</b>	04 December 2023		
<b>No. of securities held prior to change</b>		<b>Shares</b>	<b>Options</b>
	Direct	763,157	7,200,000
	Indirect	-	-
	<b>Total</b>	<b>763,157</b>	<b>7,200,000</b>
<b>Class</b>	ALAAA unlisted options		
<b>Number acquired</b>	618,000 ALAAA unlisted options		
<b>Number disposed</b>	0		
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Options issued in lieu of cash fees per Notice of AGM dated 12 October 2023		

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

No. of securities held after change		Shares	Options
	Direct	763,157	7,818,000
	Indirect	-	-
	<b>Total</b>	<b>763,157</b>	<b>7,818,000</b>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Options approved by shareholders at AGM held 10 November 2023.		

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Arovella Therapeutics Limited
<b>ABN</b>	35 090 987 250

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Michael Baker
<b>Date of last notice</b>	12 July 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect		
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Director related entity		
<b>Date of change</b>	4 December 2023		
<b>No. of securities held prior to change</b>		<b>Shares</b>	<b>Options</b>
	Direct	-	-
	Indirect	5,759,648	10,800,000
	<b>Total</b>	<b>5,759,648</b>	<b>10,800,000</b>
<b>Class</b>	ALAAA Unlisted options		
<b>Number acquired</b>	2,178,531 ALAAA unlisted options		
<b>Number disposed</b>	-		
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Options issued under LTI program for FY23.		

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

No. of securities held after change		Shares	Options
	Direct	-	-
	Indirect	5,759,648	12,978,531
	<b>Total</b>	<b>5,759,648</b>	<b>12,978,531</b>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Options approved by shareholders at AGM held 10 November 2023		

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.



# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	Arovella Therapeutics Limited
<b>ABN</b>	35 090 987 250

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Thomas Duthy
<b>Date of last notice</b>	24 August 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect		
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Director related entity		
<b>Date of change</b>	4 December 2023		
<b>No. of securities held prior to change</b>		<b>Shares</b>	<b>Options</b>
	Direct	-	-
	Indirect	4,644,444	6,521,739
	<b>Total</b>	<b>4,644,444</b>	<b>6,521,739</b>
<b>Class</b>	ALAAA Unlisted options		
<b>Number acquired</b>	319,000 ALAAA unlisted options		
<b>Number disposed</b>	-		
<b>Value/Consideration</b> <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Options issued in lieu of cash fees per Notice of AGM dated 12 October 2023		

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

No. of securities held after change		Shares	Options
	Direct	-	-
	Indirect	4,644,444	6,840,739
	<b>Total</b>	<b>4,644,444</b>	<b>6,840,739</b>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back	Issue options approved by shareholders at AGM held 10 November 2023		

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>Date of change</b>	N/A
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	N/A
<b>Interest acquired</b>	N/A
<b>Interest disposed</b>	N/A
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	N/A
<b>Interest after change</b>	N/A

## Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	N/A
<b>If prior written clearance was provided, on what date was this provided?</b>	N/A

<sup>+</sup> See chapter 19 for defined terms.